The Pharmacokinetics of Semaglutide: Why Once-Weekly Dosing Works

The GLP-1 Challenge

Native GLP-1 (glucagon-like peptide-1) has a plasma half-life of just 2 minutes, rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Creating a therapeutically viable GLP-1 receptor agonist required solving this fundamental pharmacokinetic challenge.

Molecular Engineering of Semaglutide

Semaglutide incorporates three key modifications to native GLP-1:

1. Amino acid substitution at position 8: Aib (α-aminoisobutyric acid) replaces alanine, conferring DPP-4 resistance
2. C-18 fatty diacid chain: Attached via a linker at position 26 (Lys), enabling non-covalent albumin binding
3. Amino acid substitution at position 34: Arginine replaces lysine, preventing unwanted fatty acid attachment

Albumin Binding: The Key to Once-Weekly Dosing

The C-18 fatty diacid chain binds reversibly to serum albumin (>99% bound). Since albumin has a half-life of ~19 days, this "albumin taxi" dramatically extends semaglutide's circulation time to approximately 165 hours (7 days).